Get In Touch
Have any questions or comments about the content you see on this page?
January 26, 2022
We're honored and extremely proud to be named to Bloomberg's Gender-Equality Index (GEI) for 2022, making this our second year in a row on this prestigious and important diversity, equity and inclusion benchmark. The GEI is published annually by Bloomberg - a globally recognized business and financial information and news leader, as a resource for investors. The GEI standardizes, measures and contextualizes workplace gender metrics data supplied to Bloomberg voluntarily by companies.
According to Bloomberg, "the GEI tracks the performance of public companies committed to disclosing their efforts to support gender equality through policy development, representation and transparency.”
Companies who submit for inclusion in the GEI (at no cost) use Bloomberg's standardized reporting framework. The GEI scoring methodology is comprised of two components: the amount of data disclosed and data excellence. According to Bloomberg, "Data excellence assesses a company’s performance against the key pillars of the GEI framework, in comparison with its industry peer group." Those five key pillars are:
There are also expanded areas of information requested to support the broader goal of providing more robust ESG (environmental, social, governance) data to investors.
Being recognized in the GEI for the second year in a row is exciting because it reflects Alnlyam's continued commitment to fostering a diverse, equitable, and inclusive workplace environment in which all of our employees can thrive. The COVID-19 pandemic has had a disproportionately negative effect on the work environment of women, and we are proud of how we have risen to the challenge of continuing to support our diverse workforce as we adapt and evolve our policies and practices to tackle the issues the pandemic has brought to light. - Sara Nochur, Alnylam's Chief DE&I Officer.
Included companies are not ranked. The 2022 GEI consists of 418 companies, headquartered in 45 countries and regions, across 11 sectors with a combined market capitalization of $16 trillion (USD). Alnylam was one of just 38 healthcare sector companies selected to this year's list. You can access the full list and Bloomberg's 2022 GEI Summary Report here.
The GEI brings transparency to gender-related practices and policies at publicly-listed companies, increasing the breadth of environmental, social, governance (ESG) data available to investors. At a time when it is critical for firms to demonstrate their commitment to gender equality, the companies included in this year’s index are setting an example for more transparent reporting and disclosure of social data.
For the 2022 Index, Bloomberg has added a series of questions on COVID-19 to the Framework, encompassing issues such as hiring and attrition; efforts to create an inclusive culture, work from home support, and time off, including fully paid time for bereavement.
"The changing nature of work due to the pandemic has highlighted the importance of addressing gender equality issues in a rapidly-evolving global workforce,” said Peter T. Grauer, Chairman of Bloomberg. “The Bloomberg Gender-Equality Index recognizes companies that are maintaining a strong focus on providing an inclusive work environment that supports the evolving needs of employees and retains the competitive strengths gained through gender diversity, which is increasingly critical in this challenging business environment.”
A record number of companies disclosed their data for this year's GEI by using the GEI Framework, an increase of 20% year-over-year. This demonstrates a growing commitment to gender equality and recognition that the global business community can lead the charge for meaningful change by committing to more transparent reporting and disclosure of social data.
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.Proceed to Site